ROR1 and neoplasm: It seems that IGF1R CAR T cells were more potent than ROR1 CAR T cells in suppressing tumor growth in this localized model (p < 0.01, Fig 5B and 5C) and extending survival as up to 40% of the treated mice by IGF1R CAR T cells survived to at least until at day 160 whereas no ROR1 CAR T cell treated mice survived up to day 90 (p = 0.0186).